Compare Stocks

Date Range: 

 Taro Pharmaceutical IndustriesOPKO HealthCorcept TherapeuticsViela BioOrganogenesis
SymbolNYSE:TARONASDAQ:OPKNASDAQ:CORTNASDAQ:VIENASDAQ:ORGO
Price Information
Current Price$72.18$3.42$20.45$53.01$17.92
52 Week RangeBuyBuyBuyHoldBuy
MarketRank™
Overall Score1.11.91.80.81.0
Analysis Score2.53.52.31.11.5
Community Score2.22.52.71.22.7
Dividend Score0.00.00.00.00.0
Ownership Score0.01.71.70.80.8
Earnings & Valuation Score0.61.92.50.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyHoldBuy
Consensus Price Target$81.00$9.00$24.00$57.00$17.50
% Upside from Price Target12.22% upside163.16% upside17.36% upside7.53% upside-2.34% downside
Trade Information
Market Cap$2.76 billion$2.29 billion$2.39 billion$2.91 billion$2.30 billion
Beta0.921.981.040.431.84
Average Volume28,5606,818,914569,8501,065,058827,913
Sales & Book Value
Annual Revenue$644.77 million$901.90 million$306.49 million$50 million$260.98 million
Price / Sales4.282.547.7858.268.80
Cashflow$6.51 per shareN/A$0.61 per shareN/AN/A
Price / Cash11.09N/A33.26N/AN/A
Book Value$55.15 per share$2.43 per share$3.25 per share$7.14 per share$0.59 per share
Price / Book1.311.416.297.4230.37
Profitability
Net Income$244.24 million$-314,920,000.00$94.18 million$-86,430,000.00$-40,450,000.00
EPS$6.35($0.41)$0.77($7.02)($0.42)
Trailing P/E RatioN/AN/A22.98N/AN/A
Forward P/E Ratio17.2357.0022.23N/AN/A
P/E GrowthN/A5.84N/AN/AN/A
Net Margins-45.94%-9.79%30.73%N/A-1.61%
Return on Equity (ROE)10.36%-2.61%25.38%-33.97%-10.03%
Return on Assets (ROA)8.38%-1.80%23.16%-31.49%-2.22%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.13%N/AN/A1.54%
Current Ratio2.53%1.27%10.77%19.51%1.95%
Quick Ratio2.25%0.94%10.65%19.49%1.50%
Ownership Information
Institutional Ownership Percentage11.23%28.51%75.44%46.98%4.62%
Insider Ownership Percentage13.80%40.90%16.40%31.50%57.20%
Miscellaneous
Employees1,4645,269236166910
Shares Outstanding38.26 million670.16 million116.63 million54.95 million128.21 million
Next Earnings Date5/18/2021 (Estimated)7/29/2021 (Estimated)8/3/2021 (Estimated)5/12/2021 (Estimated)8/9/2021 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableNot Optionable
SourceHeadline
Organogenesis Holdings Inc. (ORGO) CEO Gary Gillheeney on Q1 2021 Results - Earnings Call Transcript - Seeking AlphaOrganogenesis Holdings Inc. (ORGO) CEO Gary Gillheeney on Q1 2021 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 11 at 7:11 PM
Organogenesis Holdings Inc (ORGO) Q1 2021 Earnings Call Transcript - Motley FoolOrganogenesis Holdings Inc (ORGO) Q1 2021 Earnings Call Transcript - Motley Fool
fool.com - May 11 at 7:11 PM
Where Does Organogenesis Holdings Inc (ORGO) Stock Fall in the Drug Manufacturers - Specialty & Generic Field After It Has Fallen -14.71% This Week? - InvestorsObserverWhere Does Organogenesis Holdings Inc (ORGO) Stock Fall in the Drug Manufacturers - Specialty & Generic Field After It Has Fallen -14.71% This Week? - InvestorsObserver
investorsobserver.com - May 11 at 2:10 PM
Form 10-Q Organogenesis Holdings For: Mar 31 - StreetInsider.comForm 10-Q Organogenesis Holdings For: Mar 31 - StreetInsider.com
streetinsider.com - May 11 at 2:10 PM
Organogenesis (NASDAQ:ORGO)  Shares Down 6.8%  After Analyst DowngradeOrganogenesis (NASDAQ:ORGO) Shares Down 6.8% After Analyst Downgrade
americanbankingnews.com - May 11 at 12:27 PM
Organogenesis (NASDAQ:ORGO) Given New $26.00 Price Target at SVB LeerinkOrganogenesis (NASDAQ:ORGO) Given New $26.00 Price Target at SVB Leerink
americanbankingnews.com - May 11 at 11:18 AM
CORRECTING and REPLACING – Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results - Yahoo FinanceCORRECTING and REPLACING – Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results - Yahoo Finance
finance.yahoo.com - May 11 at 9:10 AM
Organogenesis Holdings Inc (ORGO) Q1 2021 Earnings Call TranscriptOrganogenesis Holdings Inc (ORGO) Q1 2021 Earnings Call Transcript
finance.yahoo.com - May 11 at 9:10 AM
Organogenesis (ORGO) Surpasses Q1 Earnings and Revenue Estimates - Yahoo FinanceOrganogenesis (ORGO) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
finance.yahoo.com - May 11 at 1:36 AM
Organogenesis Holdings Posts Q1 EPS Of $0.07 - CMLViz.com - CML NewsOrganogenesis Holdings Posts Q1 EPS Of $0.07 - CMLViz.com - CML News
cmlviz.com - May 10 at 8:35 PM
Organogenesis (ORGO) Surpasses Q1 Earnings and Revenue Estimates - NasdaqOrganogenesis (ORGO) Surpasses Q1 Earnings and Revenue Estimates - Nasdaq
nasdaq.com - May 10 at 8:35 PM
Organogenesis Holdings: Q1 Earnings Insights - BenzingaOrganogenesis Holdings: Q1 Earnings Insights - Benzinga
benzinga.com - May 10 at 8:35 PM
Organogenesis: Q1 Earnings Snapshot - San Francisco ChronicleOrganogenesis: Q1 Earnings Snapshot - San Francisco Chronicle
sfchronicle.com - May 10 at 8:35 PM
CORRECTING and REPLACING – Organogenesis Holdings Inc. - GlobeNewswireCORRECTING and REPLACING – Organogenesis Holdings Inc. - GlobeNewswire
globenewswire.com - May 10 at 8:35 PM
Organogenesis Holdings Inc. Reports First Quarter 2021 Financial ResultsOrganogenesis Holdings Inc. Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 10 at 8:35 PM
CORRECTING and REPLACING – Organogenesis Holdings Inc. Reports First Quarter 2021 Financial ResultsCORRECTING and REPLACING – Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 10 at 8:35 PM
Organogenesis (ORGO) Surpasses Q1 Earnings and Revenue EstimatesOrganogenesis (ORGO) Surpasses Q1 Earnings and Revenue Estimates
finance.yahoo.com - May 10 at 8:35 PM
Organogenesis (NASDAQ:ORGO) Updates FY 2021 Earnings GuidanceOrganogenesis (NASDAQ:ORGO) Updates FY 2021 Earnings Guidance
americanbankingnews.com - May 10 at 5:22 PM
Diabetic Foot Ulcer Therapeutic Market : Information, Figures And Analytical Insights 2021-2026-B. Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis, Inc. – The Shotcaller - The ShotcallerDiabetic Foot Ulcer Therapeutic Market : Information, Figures And Analytical Insights 2021-2026-B. Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis, Inc. – The Shotcaller - The Shotcaller
theshotcaller.net - May 10 at 10:35 AM
Organogenesis Appoints Jon Giacomin to Board of Directors - GlobeNewswireOrganogenesis Appoints Jon Giacomin to Board of Directors - GlobeNewswire
globenewswire.com - May 10 at 10:35 AM
Organogenesis Showcases Latest Advanced Wound Care - GlobeNewswireOrganogenesis Showcases Latest Advanced Wound Care - GlobeNewswire
globenewswire.com - May 8 at 8:50 AM
Zacks Investment Research Lowers Organogenesis (NASDAQ:ORGO) to HoldZacks Investment Research Lowers Organogenesis (NASDAQ:ORGO) to Hold
marketbeat.com - May 8 at 2:26 AM
Earnings Outlook for Organogenesis Holdings - BenzingaEarnings Outlook for Organogenesis Holdings - Benzinga
benzinga.com - May 7 at 1:02 PM
Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring | WHS 2021 Virtual Meeting - Yahoo FinanceOrganogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring | WHS 2021 Virtual Meeting - Yahoo Finance
finance.yahoo.com - May 6 at 10:01 PM
Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring | WHS 2021 Virtual MeetingOrganogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring | WHS 2021 Virtual Meeting
finance.yahoo.com - May 6 at 10:01 PM
05:00 ET 2020 STELLARIS Award Recipient Announced - PRNewswire05:00 ET 2020 STELLARIS Award Recipient Announced - PRNewswire
prnewswire.com - May 6 at 7:00 AM
Zacks Investment Research Downgrades Organogenesis (NASDAQ:ORGO) to HoldZacks Investment Research Downgrades Organogenesis (NASDAQ:ORGO) to Hold
marketbeat.com - April 17 at 3:20 AM
DateCompanyBrokerageAction
2/1/2021Taro Pharmaceutical IndustriesHC WainwrightBoost Price Target
2/19/2021OPKO HealthBarrington ResearchBoost Price Target
7/31/2020OPKO HealthPiper SandlerBoost Price Target
11/25/2019OPKO HealthPiper Jaffray CompaniesInitiated Coverage
8/7/2018OPKO HealthCantor FitzgeraldReiterated Rating
8/5/2020Corcept TherapeuticsJefferies Financial GroupDowngrade
2/5/2019Corcept TherapeuticsB. RileySet Price Target
8/10/2018Corcept TherapeuticsStifel NicolausReiterated Rating
2/8/2021Viela BioGuggenheimDowngrade
2/8/2021Viela BioWedbushDowngrade
7/15/2020Viela BioThe Goldman Sachs GroupUpgrade
6/3/2020Viela BioCowenReiterated Rating
5/14/2020Viela BioMorgan StanleyBoost Price Target
5/11/2021OrganogenesisSVB LeerinkLower Price Target
3/12/2021OrganogenesisCredit Suisse GroupBoost Price Target
1/14/2021OrganogenesisBTIG ResearchBoost Price Target
9/21/2020OrganogenesisOppenheimerReiterated Rating
(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.